First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade
Impact of First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade Based Therapy
Sponsor: Vanderbilt-Ingram Cancer Center
Listed as NCT01215344, this PHASE2 trial focuses on Multiple Myeloma and remains completed. Sponsored by Vanderbilt-Ingram Cancer Center, it has been updated 9 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Aug 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Nov 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vanderbilt-Ingram Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .